Telomerase, Telomerase Inhibition, and Cancer

Journal of Anti-Aging Medicine

Volumn 6, Issue 4, 2003, Pages 315-325

  Ahmed, Ali ^a   Tollefsbol, Trygve O ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

AGING; CANCER; CANCER CELL; CHROMOSOME; CHROMOSOME SIZE; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTE; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOMATIC CELL; TELOMERE;

AGING; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EUKARYOTA;

EID: 2342453957     PISSN: 10945458     EISSN: None     Source Type: Journal    
DOI: 10.1089/109454503323028911     Document Type: Review

References (98)

1. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-282.
2. Ahmed A, Tollefsbol T. Telomeres and telomerase: basic science implications for aging. J Am Geriatr Soc 2001;49:1105-1109.
3. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-352.
4. Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ. In vivo loss of telomeric repeats with age in humans. Mutat Res 1991;256:45-48.
5. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science 1990;249:1129-1133.
6. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003;361:393-395.
7. Cohen HJ. Oncology and Aging: General Principles of Cancer in the Elderly. In: Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG, eds. Principles of Geriatric Medicine and Gerontology. Vol 1. New York, McGraw-Hill, 1999, pp. 117-130.
8. Balducci L, Lyman GH. Cancer in the elderly: Epidemiologic and clinical implications. Clin Geriatr Med 1997;13:1-14.
9. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80: 1273-1283.
10. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-1929.
11. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
12. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998;58:4168-4172.
13. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795.
14. Fossel M. Telomerase and the aging cell: implications for human health. JAMA 1998;279:1732-1735.
15. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
16. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.
17. Shay JW. Telomerase in human development and cancer. J Cell Physiol 1997;173:266-270.
18. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
19. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003;17:88-100. Erratum in Genes Dev 2003;17:541.
20. Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003;17:88-100. Erratum in Genes Dev 2003;17:541.
21. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001;19:114-120.
22. Sharma HW, Sokoloski JA, Perez JR, et al. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A 1995;92:12343-12346.
23. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999;8:137-142.
24. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999;59:826-830.
25. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59: 551-557.
26. Harada K, Yasoshima M, Ozaki S, Sanzen T, Nakanuma Y. PCR and in situ hybridization studies of telomerase subunits in human non-neoplastic livers. J Pathol 2001;193:210-217.
27. Arinaga M, Shimizu S, Gotoh K, Haruki N, Takahashi T, Mitsudomi T. Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg 2000;70:401-405, discussion 405-406.
28. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000;60:2116-2121.
29. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000;28:669-677.
30. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-224.
31. Kelland LR. Telomerase: biology and phase I trials. Lancet Oncol 2001;2:95-102.
32. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999;13: 2091-2104.
33. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998;12:1769-1774.
34. Greenberg RA, O'Hagan RC, Deng H, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-1226.
35. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res 1996;68:109-182.
36. Ducrest AL, Amacker M, Mathieu YD, et al. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res 2001;61:7594-7602.
37. Vaziri H, Benchimol S. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. Oncogene 1999;18:7676-7680.
38. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 1999;59: 6087-6090.
39. Xu HJ, Zhou Y, Ji W, et al. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 1997;15: 2589-2596.
40. Oh S, Song Y, Yim J, Kim TK. The Wilms tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem 1999;274:37473-37478.
41. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
42. Kirkpatrick KL, Clark G, Ghilchick M, Newbold RF, Mokbel K. hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur J Surg Oncol 2003;29:321-326.
43. Yano Y, Yoshida K, Osaki A, et al. Expression and distribution of human telomerase catalytic component, hTERT, in human breast tissues. Anticancer Res 2002; 22:4101-4107.
44. Zaffaroni N, Della Porta C, Villa R, et al. Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. J Pathol 2002; 198:37-46.
45. Papadopoulou A, Trangas T, Teixeira MR, et al. Telomerase activity and genetic alterations in primary breast carcinomas. Neoplasia 2003;5:170-178.
46. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999;21: 115-118.
47. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-468.
48. Arai T, Yasuda Y, Takaya T, et al. Application of telomerase activity for screening of primary lung cancer in broncho-alveolar lavage fluid. Oncol Rep 1998;5: 405-408.
49. Dikmen E, Kara M, Dikmen G, Cakmak H, Dogan P. Detection of telomerase activity in bronchial lavage as an adjunct to cytological diagnosis in lung cancer. Eur J Cardiothorac Surg 2003;23:194-199, discussion 199-120.
50. Bednarek AK, Sahin A, Brenner AJ, Johnston DA, Aldaz CM. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res 1997;3:11-16.
51. Qiu XG, Liu YP, Pu QT, Gu QH, Han JJ. Significance of telomerase expression in diagnosis and treatment of breast tumor. Ai Zheng 2002;21:1241-1243 [in Chinese].
52. Hiyama E, Saeki T, Hiyama K, et al. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples. Cancer 2000;90:235-238.
53. Ishibashi K, Hirose K, Kato H, Ogawa K, Haga S. Determining the telomerase activity of exfoliated cells in intestinal lavage solution to detect colorectal carcinoma. Anticancer Res 1999;19:2831-2836.
54. Boldrini L, Faviana P, Gisfredi S, et al. Evaluation of telomerase mRNA (hTERT) in colon cancer. Int J Oncol 2002;21:493-497.
55. Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol 2003;15:75-80.
56. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-673.
57. Erdem E, Dikmen G, Atsu N, Dogan P, Ozen H. Telomerase activity in diagnosis of bladder cancer. Scand J Urol Nephrol 2003;37:205-209.
58. Aogi K, Kitahara K, Buley I, et al. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 1998;4:1965-1970.
59. Suzuki S, Fukushima T, Ami H, Onogi H, Nakamura I, Takenoshita S. New attempt of preoperative differential diagnosis of thyroid neoplasms by telomerase activity measurement. Oncol Rep 2002;9:539-544.
60. Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997;57:326-331.
61. Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepatogastroenterology 2001;48: 933-938.
62. Kojima H, Yokosuka O, Kato N, et al. Quantitative evaluation of telomerase activity in small liver tumors: analysis of ultrasonography-guided liver biopsy specimens. J Hepatol 1999;31:514-520.
63. Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K. Elevated levels of telomerase activity in malignant pheochromocytoma. Cancer 1998;82:176-179.
64. Itoi T, Shinohara Y, Takeda K, et al. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. Gastrointest Endosc 2000;52: 380-386.
65. Itoi T, Ohyashiki K, Yahata N, et al. Detection of telomerase activity in exfoliated cancer cells obtained from bile. Int J Oncol 1999;15:1061-1067.
66. Murakami J, Nagai N, Ohama K. Telomerase activity in body cavity fluid and peritoneal washings in uterine and ovarian cancer. J Int Med Res 1998;26: 129-139.
67. Wen J, Sun L, Zhang M, Zheng MH. Telomerase activation in malignant bone tumors. Mol Diagn 1998;3:29-35.
68. Hodes R. Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci U S A 2001;98:7649-7651.
69. Misawa M, Tauchi T, Sashida G, et al. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 2002; 21:1087-1092.
70. Nakajima A, Tauchi T, Sashida G, et al. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 2003;17:560-567.
71. Kondo S, Kondo, Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998;16:3323-3330.
72. Wong SC, Yu H, Moochhala SM, So JB. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Res 2003;23: 465-469.
73. Yatabe N, Kyo S, Kondo S, et al. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 2002;9:624-630.
74. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-679.
75. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 2000;97:4796-4801.
76. Nair SK, Heiser A, Boczkowski D, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-1017.
77. Lin Z, Lim S, Viani MA, Sapp M, Lim MS. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 2001;159:711-719.
78. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392:569-574.
79. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 1999;25:241-248.
80. Herbert BS, Wright AC, Passons CM, et al. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst 2001;93:39-45.
81. Kumaki F, Kawai T, Hiroi S, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001;32: 188-195.
82. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 1999;20: 1649-1651.
83. Kimura M, Koida T, Yanagita Y. A study on telomerase activity and prognosis in breast cancer. Med Oncol 2003;20:117-126.
84. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000;6:2696-2701.
85. Poremba C, Heine B, Diallo R, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002;198:181-189.
86. Mokbel K, Parris CN, Ghilchik M, Williams G, Newbold RF. The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am J Surg 1999;178:69-72.
87. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997; 89:1874-1881.
88. Devemy E, Li B, Tao M, et al. Poor prognosis acute myelogenous leukemia: 3 - biological and molecular biological changes during remission induction therapy. Leuk Res 2001;25:783-791.
89. Verstovsek S, Kantarjian H, Manshouri T, et al. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 2003;97:1248-1252.
90. Ahmed A, Tollefsbol T. Telomeres, telomerase, and telomerase inhibition: clinical implications for cancer. J Am Geriatr Soc 2003;51:116-122.
91. Ren JG, Xia HL, Just T, Dai YR. Hydroxyl radical-induced apoptosis in human tumor cells is associated with telomere shortening but not telomerase inhibition and caspase activation. FEBS Lett 2001;488: 123-132.
92. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999;13: 2388-2399.
93. Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res 1997;57:1863-1867.
94. Zhang X, Chen Z, Chen Y, Tong T. Delivering antisense telomerase RNA by a hybrid adenovirus/ adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells. Oncogene 2003;22:2405-2416.
95. Suenaga M, Soda H, Oka M, et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002;97:621-625.
96. Nakamura M, Saito H, Ebinuma H, et al. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J Cell Physiol 2001; 187:392-401.
97. Shimada M, Hasegawa H, Gion T, et al. The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol 2000;95:748-752.
98. Ebina Y, Yamada H, Fujino T, et al. Telomerase activity correlates with histo-pathological factors in uterine endometrial carcinoma. Int J Cancer 1999;84: 529-532.